US EditionPublished • loading... • Updated
HaemaLogiX wins "Most Promising CAR-T Pipeline in APAC" at the Asia Pacific CGT¹ Excellence Awards 2025
- HaemaLogiX Ltd won the "Most Promising CAR-T Pipeline in APAC" award at the Asia Pacific CGT Excellence Awards 2025, which took place in Singapore on September 10, 2025.
- The award acknowledges HaemaLogiX's innovation in developing immunotherapies targeting unique cancer cell antigens, Kappa Myeloma Antigen and Lambda Myeloma Antigen .
- Approximately 188,000 new cases of multiple myeloma are diagnosed globally each year, highlighting the need for effective treatment options, as around 60% of patients do not respond to standard care.
- Rosanne Dunn, Founder and Chief Scientific Officer of HaemaLogiX, expressed that this award recognizes their dedication to advancing therapies for multiple myeloma, for which there is currently no cure.
Insights by Ground AI
69 Articles
69 Articles
HaemaLogiX wins 'Most Promising CAR-T Pipeline in APAC' at the Asia Pacific CGT¹ Excellence Awards 2025
SYDNEY, Sept. 11, 2025 /PRNewswire/ -- HaemaLogiX Ltd, a clinical stage Australian biotech, developing novel immunotherapies for patients with blood cancers and B-cell diseases,...
·Manila, Philippines
Read Full Article
Bennington Banner+67 Reposted by 67 other sources
HaemaLogiX wins "Most Promising CAR-T Pipeline in APAC" at the Asia Pacific CGT¹ Excellence Awards 2025
SYDNEY, Sept. 10, 2025 /PRNewswire/ -- HaemaLogiX Ltd, a clinical stage Australian biotech, developing novel immunotherapies for patients with blood cancers and B-cell diseases, was honoured to be awarded the "Most Promising CAR-T Pipeline in APAC" at the Asia Pacific…
Coverage Details
Total News Sources69
Leaning Left7Leaning Right6Center18Last UpdatedBias Distribution58% Center
Bias Distribution
- 58% of the sources are Center
58% Center
L 23%
C 58%
R 19%
Factuality
To view factuality data please Upgrade to Premium
